RxDoctor Payments Data

Bino Oommen, MD

Internal Medicine · Des Plaines, ILNPI 1235315995

Payments from drug & device makers

$2,754in general payments, 2019–2025

Across 82 payments — averaging $33.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$876
  • Novo Nordisk$526
  • Corcept Therapeutics$321
  • Johnson & Johnson$296
  • Abbott$165
  • Pfizer$136
  • plus $434 from 14 others

What the payments were for

  • Food & beverage$2,72899%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,754 in reported general payments places this provider in the 85th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$1,018,854
Medicare patients
443
Services billed
19,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban175$118,932
JardianceEmpagliflozin31$21,769
XareltoRivaroxaban28$17,589
MyrbetriqMirabegron17$12,193
JanuviaSitagliptin Phosphate14$9,220
Tresiba Flextouch U-100Insulin Degludec17$8,372
FarxigaDapagliflozin Propanediol11$7,772
LinzessLinaclotide13$7,164
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$6,895
Sevelamer Carbonate16$5,418
Atorvastatin Calcium424$5,227
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$4,711
Bumetanide140$4,376
Humalog Kwikpen U-100Insulin Lispro24$4,092
Pantoprazole Sodium251$3,901

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$136$118,932175 claims
Johnson & JohnsonXarelto$296$17,58928 claims
AbbVieLinzess$17$7,16413 claims
GSKTrelegy Ellipta$23$6,89513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Des Plaines

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →